S&P Global Ratings has 10 public ratings on Maryland not-for-profit acute-care providers, split evenly between health systems and stand-alone hospitals. We also rate Maryland-based Bon Secours Mercy Health, although we have excluded it from this ratio analysis because the system no longer operates acute-care hospitals in the state. Given that the state and location in which providers operate can significantly influence health-care delivery, from underlying demographic trends to the legislative and competitive environment, market-specific factors provide a crucial backdrop for our analysis of an entity's overall credit profile. This report aims to provide greater analytical insights from the sample of issuers compared with acute-care providers across the country and to supplement our top-level and national credit views on the not-for-profit health-care sector.
The Global Budget Is Strained After Years Of Stability
Maryland health-care providers operate under a unique waiver program, an all-payer-rate system (Maryland's Global Budget Agreement or Maryland's Medicare waiver) regulated by a state agency, the Health Services Cost Review Commission (HSCRC). Historically, HSCRC has set all rates for inpatient and outpatient cases at each hospital (for both commercial and governmental payers), with a goal to keep growth in cost per case below the national average growth for Medicare cases. In January 2014, the Centers for Medicare and Medicaid Services, through the organization's Center for Medicare and Medicaid Innovation, approved a waiver for Maryland for an initial five-year period. Under the 2014 waiver, HSCRC redesigned its payment system as a global budget model to fix revenues and include more incentives for hospitals to control unnecessary use and improve population health. Therefore, all Maryland hospitals are at risk for managing use and cost. However, global budgets could be adjusted for market share and population changes.
Although the program was not a full-risk or capitation model, the global budget shifted incentives to focus on appropriate volume and patients' health status and was an intermediate step toward population health. In addition, hospitals that reduced readmissions and other inappropriate use generated stronger profitability in the early years under the global budget program. A new waiver went into effect Jan. 1, 2019, for a 10-year term and expanded the global budget to a total cost-of-care model, shifting the focus beyond care in the traditional hospital setting, encouraging primary care providers to play an increased role in the prevention and management of chronic diseases, and seeking to further prevent unnecessary hospitalization.
Historically, we have viewed this payment system as providing stability, given the predictability of an established revenue base, and providers' challenge has been to manage volumes and expenses to maintain debt service coverage levels. The model also provided stability through the COVID-19 pandemic as the HSCRC took actions, including limiting revenue volatility through increased rate corridors and allowing providers to carry forward unreimbursed revenue into future fiscal years. However, a key tenet of the waiver establishes targets to keep Medicare cost growth in Maryland lower than national levels, which was not achieved in the past year. Therefore, the HSCRC has reduced rates to constrain cost growth and re-align with the waiver's targets, and many hospitals could see smaller revenue increases in the next calendar year. Although most of the providers rated by S&P Global Ratings have reported moderate reductions, the lower rates could further strain financial performance, particularly as the industry experiences ongoing staffing and inflationary pressure. Furthermore, if revenue growth remains stagnant and does not adequately offset rising expenses, or if management teams are unable to offset this with cost savings or efficiencies, providers could experience continued weakening operating performance and cash flow, which could lead us to lower ratings or revise outlooks to negative for many of the rated providers in the state. For more information on pressures we're monitoring for the overall sector, see "Outlook For U.S. Not-For-Profit Acute Health Care: A Long Road Ahead," published Dec. 1, 2022, on RatingsDirect.
Maryland's Strong Economic Indicators Benefit Health Care Organizations' Enterprise Profile Characteristics
Our rating on the state of Maryland is 'AAA', which is, in part, attributed to the state's very strong wealth and income indicators and a relatively diversified economic base that have contributed to its recent economic recovery and better-than-forecast revenue performance. Furthermore, employment is somewhat concentrated in the federal government sector, providing some stability to the economy, and limiting the effects on the state's economy during periods of economic expansion and contraction. For more information on the state rating, see our most recent full analysis, published March 8, 2023. Health-care systems and stand-alone hospitals operating within Maryland benefit from similar characteristics, exhibiting healthy economic fundamentals.
Despite the relatively small number of rated issuers in Maryland, these acute-care providers operate about half of the hospitals in the state and serve a broad range of service area populations, ranging from about 150,000 to more than 6 million. While there is limited reach beyond the state among the issuers we rate, some providers have geographic reach and facilities in nearby states, as well as a national draw for Maryland's well-regarded academic medical centers. A majority of the acute health-care providers in Maryland rated by S&P Global Ratings have economic fundamentals we consider very strong or strong based on their service area population, with those smaller providers in more rural regions considered adequate. Furthermore, given the state's economic strength, almost all Maryland providers exhibit neutral or positive economic indicators as per our criteria for population, employment growth, and per capita income compared with U.S. national averages, helping to support solid demand characteristics.
Maryland providers also exhibit solid market positions, with the majority scoring very strong and the rest strong. The state is home to well-known academic medical centers, including Johns Hopkins Health System and the University of Maryland Medical System. The state's model generally encourages providers to collaborate and lessens direct competition, particularly for inpatient care, although we still consider many markets in the state to be competitive. At times, aggressive growth and disruptions to patient patterns could result in delayed recalibration of the global budget to capture additional revenue. Furthermore, Maryland is a certificate-of-need state, which prohibits health-care providers from entering new markets or making changes to their existing capacity without first gaining the approval of state regulators. We also view the state's rate-setting program positively as the program diminishes the effect of the payer mix in our credit rating analysis. The state's providers also generally exhibit good quality scores, which are partially attributable to the global budget model's focus on population health. Along with generally solid management and governance scores, all of the rated Maryland providers have an overall enterprise profile score of strong or very strong, which is slightly better than that for the overall rated acute-care sector.
Modest Cash Flow And A Competitive Market Spur Higher Capital Expenditures And Elevated Debt Profiles
Maryland's unique payer system has historically afforded stability to financial metrics, although medians for key metrics are relatively weaker for state providers compared with those of the overall rated sector. Although operating margins have generally been stable and positive for Maryland providers, they are also slightly weaker compared with those of similarly rated peers operating in different states. Because revenue growth is generally more restrained, providers are incentivized to contain expenses, which can be seen in slightly lower salaries and benefits over net patient revenue compared with those of other providers that we rate. Given the limited flexibility on revenue growth, one-time impacts such as electronic medical record transitions or acquisitions could cause short-term operating pressure. Moderate operating income, combined with generally favorable nonoperating income, contributes to steady but modest cash flow, but typically limits any rapid or above-average growth in unrestricted reserves.
Many Maryland providers operate in large, competitive markets, spurring healthy capital investment. Capital expenditures and average age of plant have compared favorably with the overall sector; however, as historical cash flow tends to be below that of similarly rated organizations, providers tend to rely on a higher proportion of debt to fund capital investment, resulting in higher debt levels and debt-related metrics. In addition, slower appreciation in unrestricted net assets contributes to the somewhat weaker leverage. Unrestricted reserves-to-long-term debt, maximum annual debt service coverage, and debt burden are weaker than overall medians. Unrestricted reserves, however, have seen continual growth that, in conjunction with cost containment incentivized by the global budget model, generates days' cash on hand that is favorable compared with the overall sector in the past several years.
Fiscal 2022 medians highlight the expected trend of weakening financial performance, largely spurred by elevated labor expenses and inflation, as well as less stimulus funding. Unrestricted reserves have also deteriorated because investment market volatility has resulted in significant unrealized losses for many Maryland providers as well as the larger sector. Preliminary fiscal 2023 interim results indicate incremental improvement in financial performance and unrestricted reserves, although we anticipate expense pressures will persist through 2023 and potentially in future years.
As applicable in 2020, 2021, and 2022, and consistent with S&P Global Ratings' practice, Medicare advance payments and other short-term borrowings for operations are excluded from unrestricted reserves, contingent liabilities, and long-term debt. Recognized pandemic provider relief funds are included in operating revenue, and some organizations entered fiscal 2022 with some grants left unrecognized. Full 2022 medians for acute-health-care issuers rated by S&P Global Ratings will be published later this summer. One fiscal 2022 audit was unavailable for this report.
|Maryland not-for-profit acute health care medians|
|Maryland||All acute care|
|Net patient revenue ($000s)||1,086,322||975,581||921,189||782,226||996,903||900,920||922,974|
|Total operating revenue ($000s)||1,132,511||1,125,855||1,005,897||813,812||1,176,202||1,046,825||1,014,342|
|Total operating expenses ($000s)||1,198,236||1,116,072||999,105||800,970||1,118,932||MNR||MNR|
|Operating income ($000s)||8,968.0||34,873||(329)||13,921||26,168||MNR||MNR|
|Operating margin (%)||0.6||2.8||0.0||1.4||2.8||1.6||2.3|
|Net nonoperating income ($000s)||46,527||24,664||14,329||18,358||34,789||MNR||MNR|
|Excess income ($000s)||53,387||63,874||13,902||35,184||67,603||MNR||MNR|
|Excess margin (%)||2.9||4.6||2.0||3.1||6.0||3.4||4.1|
|Operating EBIDA margin (%)||6.2||7.9||7.0||8.5||8.6||7.6||8.4|
|EBIDA margin (%)||9.0||10.3||8.6||9.9||11.7||9.5||10.0|
|Net available for debt service ($000s)||110,612||110,622||89,344||82,428||139,751||90,167||100,739|
|Maximum annual debt service ($000s)||36,313||37,510||37,510||37,510||26,402||MNR||MNR|
|Maximum annual debt service coverage (x)||3.8||4.5||2.8||3.3||5.4||3.9||3.9|
|Operating lease-adjusted coverage (x)||3.2||3.3||2.5||2.7||4.1||3.1||3.2|
|Liquidity and financial flexibility|
|Unrestricted reserves ($000s)||522,658||592,213||439,354||393,942||819,247||680,185||553,019|
|Unrestricted days' cash on hand||217.1||256.3||204.3||219.7||250.0||232.9||210.2|
|Unrestricted reserves/total long-term debt (%)||140.6||149.6||109.0||125.4||211.7||192.5||181.5|
|Unrestricted reserves/contingent liabilities (%)*||458.0||490.2||326.8||318.3||895.9||775.4||650.1|
|Average age of plant (years)||11.9||11.9||11.6||10.6||12.2||11.8||11.5|
|Capital expenditures/depreciation and amortization (%)||123.9||117.1||117.2||105.2||107.4||112.9||119.3|
|Debt and liabilities|
|Total long-term debt ($000s)||434,739||534,328||515,892||468,241||360,330||MNR||MNR|
|Long-term debt/capitalization (%)||38.5||38.6||45.8||44.6||27.8||29.9||29.2|
|Contingent liabilities ($000s)*||175,997||147,338||133,507||137,273||134,075||MNR||MNR|
|Contingent liabilities/total long-term debt (%)*||26.1||28.8||31.1||36.1||25.7||26.6||28.7|
|Debt burden (%)||2.3||2.6||2.8||2.9||2.2||2.4||2.4|
|Defined-benefit plan funded status (%)*||99.5||83.9||76.4||81.3||91.4||80.7||81.8|
|Salaries & benefits/NPR (%)||58.6||56.6||58.1||56.0||57.6||60.2||56.7|
|Nonoperating revenue/total revenue (%)||3.5||1.6||1.4||1.7||2.9||1.8||1.9|
|Cushion ratio (x)||21.3||21.4||16.3||15.7||27.8||24.8||23.0|
|Days in accounts receivable||42.1||42.0||41.4||41.7||47.4||45.1||47.6|
|Cash flow/total liabilities (%)||10.7||12.9||7.2||10.0||16.1||11.6||15.5|
|Pension-adjusted long-term debt/capitalization (%)*||38.7||38.7||46.0||44.9||29.0||32.1||31.7|
|Nonrecurring operating income adjusted operating margin (%)§||0.0||0.0||(3.3)||MNR||0.6||(2.4)||MNR|
|MNR--median not reported. *These ratios are only for organizations that have defined-benefit (DB) pension plans, operating leases, or contingent liabilities. §Nonrecurring operating income is largely attributable to COVID-19 stimulus funds recognized, but could be comprised of other non recurring items.|
Maryland Issuer Ratings
Table 2 lists all Maryland-based not-for-profit acute health-care providers publicly rated under our "U.S. And Canadian Not-For-Profit Acute Care Health Care Organizations" criteria, published March 19, 2018.
|Maryland not-for-profit acute health care ratings and outlooks as of March 31, 2023|
|Greater Baltimore Medical Center||A||Negative||Stand-alone|
|Johns Hopkins Health System Obligated Group||AA-||Stable||System|
|LifeBridge Health Inc.||A+||Stable||System|
|MedStar Health Inc.||A||Stable||System|
|Mercy Health Services||BBB+||Positive||Stand-alone|
|Meritus Health Inc.||BBB+||Positive||Stand-alone|
|University of Maryland Medical System||A||Stable||System|
The rating distribution for Maryland providers skew to the middle of the rating scale in line with the broader portfolio, with the majority of issuers rated in the 'A' category. Three are rated in the 'BBB' category and one in the 'AA' category. There are no Maryland providers in the speculative-grade category, which is attributable to the general stability in financial metrics and strong enterprise characteristics.
There has been limited movement in ratings over the past several years, with just one upgrade since 2020, as well as one new issuer in 2021. Although ratings have remained relatively stable since 2021, there has been an uptick in outlook revisions, particularly through 2023, when we revised the outlooks on two providers to negative and revised the outlook on another to positive.
|Maryland not-for-profit acute health care rating actions|
|Adventist Healthcare||BBB||Stable||NR||NR||New issuer|
|Meritus Health, Inc.||BBB+||Positive||BBB||Stable||Upgrade|
|No rating actions|
|Greater Baltimore Medical Center||A||Negative||A||Stable||Revised outlook to negative|
|TidalHealth, Inc.||A||Negative||A||Stable||Revised outlook to negative|
|Mercy Health Services||BBB+||Positive||BBB+||Stable||Revised outlook to positive|
|*2023 Rating Actions through March 31, 2023|
Although the number of issuers is relatively small, 50% of the ratings have a positive or negative outlook, compared with about 25% within the broader sector.
Elsa Berisha contributed research to this report.
This report does not constitute a rating action.
|Primary Credit Analysts:||Chloe A Pickett, Englewood + 1 (303) 721 4122;|
|Stephen Infranco, New York + 1 (212) 438 2025;|
|Secondary Contact:||Suzie R Desai, Chicago + 1 (312) 233 7046;|
No content (including ratings, credit-related analyses and data, valuations, model, software, or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced, or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of Standard & Poor’s Financial Services LLC or its affiliates (collectively, S&P). The Content shall not be used for any unlawful or unauthorized purposes. S&P and any third-party providers, as well as their directors, officers, shareholders, employees, or agents (collectively S&P Parties) do not guarantee the accuracy, completeness, timeliness, or availability of the Content. S&P Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an “as is” basis. S&P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED, OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.
Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P’s opinions, analyses, and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment, and experience of the user, its management, employees, advisors, and/or clients when making investment and other business decisions. S&P does not act as a fiduciary or an investment advisor except where registered as such. While S&P has obtained information from sources it believes to be reliable, S&P does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives. Rating-related publications may be published for a variety of reasons that are not necessarily dependent on action by rating committees, including, but not limited to, the publication of a periodic update on a credit rating and related analyses.
To the extent that regulatory authorities allow a rating agency to acknowledge in one jurisdiction a rating issued in another jurisdiction for certain regulatory purposes, S&P reserves the right to assign, withdraw, or suspend such acknowledgement at any time and in its sole discretion. S&P Parties disclaim any duty whatsoever arising out of the assignment, withdrawal, or suspension of an acknowledgment as well as any liability for any damage alleged to have been suffered on account thereof.
S&P keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain business units of S&P may have information that is not available to other S&P business units. S&P has established policies and procedures to maintain the confidentiality of certain nonpublic information received in connection with each analytical process.
S&P may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P reserves the right to disseminate its opinions and analyses. S&P's public ratings and analyses are made available on its Web sites, www.spglobal.com/ratings (free of charge), and www.ratingsdirect.com (subscription), and may be distributed through other means, including via S&P publications and third-party redistributors. Additional information about our ratings fees is available at www.spglobal.com/usratingsfees.